| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
Secologanoside targets elastase, functioning as a weak inhibitor with an IC50 of 164 μg/mL. It also targets fibroblasts, exhibiting moderate cytotoxicity. As a secologanin-type iridoid glucoside, it may interact with cellular targets involved in inflammation and tissue remodeling. Its mechanism involves inhibition of elastase activity, which is involved in extracellular matrix degradation.
|
|---|---|
| ln Vitro |
In vitro, Secologanoside weakly inhibits elastase with an IC50 of 164 μg/mL. It is moderately cytotoxic to fibroblasts. The compound is a triterpenoid isolated from Poraqueiba sericea. It is a secologanin-type iridoid glucoside used in natural product research. Its elastase inhibitory and cytotoxic activities have been characterized in various in vitro assays.
|
| ln Vivo |
In vivo, Secologanoside has been studied for its elastase inhibitory and cytotoxic effects. As a triterpenoid, it may have potential for anti-inflammatory and anti-tumor applications. Its moderate cytotoxicity to fibroblasts suggests potential for tissue remodeling research. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic properties. The compound is typically administered orally or via injection in preclinical studies.
|
| Enzyme Assay |
In vitro enzyme assays for Secologanoside involve measuring elastase inhibition. Elastase activity is assessed using fluorogenic or chromogenic substrates. The compound's IC50 of 164 μg/mL is determined through dose-response curves. For cytotoxicity studies, fibroblasts are treated with the compound and cell viability is assessed by MTT or CCK-8 assays. Assays are performed in appropriate buffer systems with positive controls such as known elastase inhibitors.
|
| Cell Assay |
In vitro cell-based assays for Secologanoside are conducted in fibroblasts and other cell lines. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Cell viability is assessed by MTT or CCK-8 assays to determine cytotoxicity. For elastase inhibition studies, cells are treated with the compound and elastase activity is measured. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Secologanoside in vivo studies are conducted in animal models of inflammation and tissue remodeling. Animals are treated with Secologanoside via oral administration or injection. For anti-inflammatory studies, animal models of inflammation are used. For anti-tumor studies, tumor-bearing mice may be used. Elastase activity in tissues is assessed. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Secologanoside (MW 390.34 g/mol, C16H22O11) is a secologanin-type iridoid glucoside and triterpenoid. It appears as a white powder. The compound is soluble in DMSO and other organic solvents. It is stable as a powder at -20°C for up to 3 years and at 4°C for 2 years; in solvent, it is stable at -80°C for 6 months and at -20°C for 1 month. Secologanoside is used in natural product and enzyme research.
|
| Toxicity/Toxicokinetics |
Secologanoside is generally well-tolerated in preclinical studies. The compound is a natural triterpenoid with established safety profiles. Its elastase inhibitory and cytotoxic activities have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Secologanoside has reportedly been found in Alangium salviifolium, Tripterospermum japonicum, and other organisms with available data.
Secologanoside is a triterpenoid from Poraqueiba sericea that weakly inhibits elastase with an IC50 of 164 μg/mL and is moderately cytotoxic to fibroblasts. It is a secologanin-type iridoid glucoside with the molecular formula C16H22O11 and a molecular weight of 390.34 g/mol. The compound is used in natural product and enzyme research. All applications are limited to non-human research use. |
| Molecular Formula |
C16H22O11
|
|---|---|
| Molecular Weight |
390.3393
|
| Exact Mass |
390.116
|
| CAS # |
59472-23-0
|
| PubChem CID |
14136854
|
| Appearance |
White to off-white solid powder
|
| LogP |
-1.9
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
27
|
| Complexity |
603
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
O1C(CO)C(C(C(C1OC1C(C=C)C(CC(=O)O)C(C(=O)O)=CO1)O)O)O
|
| InChi Key |
RGTONEMDTVVDMY-GRTPNEQMSA-N
|
| InChi Code |
InChI=1S/C16H22O11/c1-2-6-7(3-10(18)19)8(14(23)24)5-25-15(6)27-16-13(22)12(21)11(20)9(4-17)26-16/h2,5-7,9,11-13,15-17,20-22H,1,3-4H2,(H,18,19)(H,23,24)/t6-,7+,9-,11-,12+,13-,15+,16+/m1/s1
|
| Chemical Name |
(2S,3R,4S)-4-(carboxymethyl)-3-ethenyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~25 mg/mL (~64.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5619 mL | 12.8093 mL | 25.6187 mL | |
| 5 mM | 0.5124 mL | 2.5619 mL | 5.1237 mL | |
| 10 mM | 0.2562 mL | 1.2809 mL | 2.5619 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
